Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with ...
aDepartment of Pediatrics, New York University Grossman School of Medicine, New York, NY, USA bDepartment of Population Health, New York University Grossman School of Medicine, New York, NY, USA ...
In September 2025, analysts highlighted that the FDA waived the advisory committee meeting for Aquestive Therapeutics’ New Drug Application for Anaphylm, a needle-free, orally delivered epinephrine ...
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa ...
Aquestive Therapeutics (NASDAQ:AQST), a biopharmaceutical company specializing in orally administered therapeutics, is garnering attention from investors and analysts alike as it approaches a critical ...
In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function compared with placebo Dexpramipexole demonstrated statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback